Navigation Links
Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease
Date:7/14/2009

BROOMFIELD, Colo., July 14 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, today announced further evidence for genetic interactions impacting the efficacy of the ketogenic compound AC-1202 (Axona(TM)) in Alzheimer's disease. New data from the company's previously completed double-blind, placebo-controlled trial in patients with mild-to-moderate Alzheimer's disease demonstrates an interaction between two genetic markers that strongly influence the therapeutic response in patients. Dr. Samuel Henderson, Executive Director of Research, will present these results at the 2009 International Conference on Alzheimer's Disease (ICAD) sponsored by the Alzheimer's Association.

During this study, patients received daily administration of either AC-1202 or placebo for 90 days, with efficacy assessments performed at Baseline (Day 0), Day 45, Day 90 and after a two week washout from their assigned product on Day 104. In addition, analyses of a number of genotypic markers judged to be relevant to the physiological background of Alzheimer's disease were also performed.

Previous analysis of the study revealed that patients administered AC-1202 who lacked the epsilon 4 variant of the APOE gene (E4(-)), demonstrated significant improvement from baseline values in the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) and improvement compared to placebo of 4.77 at Day 45 and 3.36 at Day 90 (p <0.05). ADAS-Cog, a neuropsychometric battery of tests that measures short-term memory and cognition, is probably the most widely used cognitive instrument used in clinical trials of anti-dementia drugs within the United States and Europe. Numerous clinical studies have demonstrated that modest improvements in ADAS-cog scores - on the order of 2 to 3 points over the course of a year - have been associated with sign
'/>"/>

SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. Evidence of macroscopic quantum tunneling detected in nanowires
3. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
4. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
5. ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009
6. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
7. Evidence of Ancient Hot Springs on Mars Detailed in Astrobiology Journal
8. Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol
9. The Lancets New Online Medical Journal Helps Clinicians and Medical Researchers Find Practice-Changing Evidence Quickly and Easily
10. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
11. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...Md., Nov. 20 Novavax, In...iced an underwritten public offering of 6,800,000 ...c of $3.30 per share. The approximately $21 milli...ng discounts and commissions, will be used for pre...sed vaccines, internal research and development pr...
(Date:11/20/2009)... METTLER TOLEDO recently announced that Dr. Domin...The Role of Process Analytical Technology (PAT) in...ecember 1, 2009. , (PRWEB...cess Analytical Technology (PAT) in Green Chemistr...ocess Analytical Technology (PAT) case studies wil...
(Date:11/19/2009)...., Nov. 19 Dr. Mate Hidvegi, inven...ds to a press release issued on November 17 by Bir...r making false and self-serving statements about i.... Hidvegi stated from his office in Budapest, Hung... Avemar does not apply to AveULTRA, www.aveultra...
(Date:11/19/2009)...Pa. and WALTHAM, Mass., Nov. 19 Ar...rces find that the leading driver of antibiotic se...-spectrum activity against gram-positive and gram-...s that can cause nosocomial pneumonia, surveyed Eu...for agents that provide appropriate coverage again...
Breaking Biology Technology:Novavax Prices Public Offering of Common Stock 2Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...ovides supplemental recognition factor to assist i...on, INDIANAPOLIS, Oct. 27 Eli Lilly and Company,...a color differentiation,system for U-100 insulin p...ials, pens and individual packaging for Humalog(R)...lin(R) (regular insulin human injection,USP [rDNA ...
...ATTLE, Oct. 27 Trubion Pharmaceuticals Inc.,(Nasd...hase 1/2a study,demonstrating that repeat administ...t responses and significant improvements in rheuma...erican College of Rheumatology (ACR),criteria. Tru...liminary,analyses from a Phase 2b study in which p...
...nagement to Host Conference Call at 8:30 a.m. East...ss Results, BIRMINGHAM, Ala., Oct. 27 BioCryst,P...ced results of an,exploratory Phase 2 trial of int...or, in patients hospitalized for acute serious or ...2 trial compared the efficacy and,safety of five d...
Other Biology Technology:Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 2Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 3Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 4Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 5Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
(Date:11/20/2009)... estimated 4.6 million Americans involved in the e...atory symptoms due to poor air quality in horse ba... earlier this year by investigators at Tufts Unive... The studywhich polled more than 80 New England h...als working in barns complained of coughing, wheez...
(Date:11/20/2009)...shives, and generated from Brassica carinata , a ...f fields in spring, can be used to produce bioetha...d out by Spanish and Dutch researchers and publish...y Reviews . , "These studies evaluate, from an en...hanol from two, as yet unexploited sources of biom...
(Date:11/19/2009)...d of the last ice age, North America,s vast assemb...ures as mammoths, mastodons, camels, horses, groun...s slide to extinction. , And when their populati...rge animals equaled or surpassed Africa,s wildlife...vel ecosystem emerged as broadleaved trees once ke...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 1Ten Professional Societies Join Forces to Develop Obesity Medicine Certification Examination 53683 2Neuropathic pain 3A The sea provides a new hope of relief 9475 1Neuropathic pain 3A The sea provides a new hope of relief 9475 2Demi Lovato Joins National Bullying Prevention Movement 53681 1Demi Lovato Joins National Bullying Prevention Movement 53681 2
...gists at Washington University in St. Louis shows ...rea, the less chance humans have of exposure to We...birds. , "The bottom line is that where there are ...lower risk of contracting West Nile Fever," said B...& Sciences at Washington University in St. Louis. ...
...James D. Rives Professor of Surgery and Neuroscien...ol of Medicine, and Dr. Conrad Hornick, former LSU...S Patent for a compound to inhibit the formation o...s tumors and diseases like diabetic retinopathy, o...e major protein component of lipoproteins water so...
...sing nanotechnology to search for new cancer-fight...,000 times faster than current methods. , The "La...ls simultaneously using tiny plastic beads so smal.... Each bead carries a separate chemical, which ca...s needed to treat cancer cells. One batch of nano...
Other Biology News:Study: Bird diversity lessens human exposure to West Nile Virus 2LSUHSC awarded patent for compound inhibiting cancer and other diseases 2Nanoscopic screening process to speed drug discovery 2
Goat Anti-SMAD7, MADH7 Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human PRG3 Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-C3a / C3a des Arg Monoclonal Antibody, Unconjugated, Clone 2991 from Abcam
Mouse Anti-DNA-PKcs, phospho (Thr2609) Monoclonal Antibody, Unconjugated, Clone 10B1 from BioLegend
Biology Products: